Headlines about TG Therapeutics (NASDAQ:TGTX) have been trending somewhat positive on Tuesday, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. TG Therapeutics earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.3888978594844 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media headlines that may have effected Accern’s rankings:
- Short Interest in TG Therapeutics Inc (TGTX) Declines By 15.0% (americanbankingnews.com)
- TG Therapeutics (TGTX) Posts Earnings Results, Hits Estimates (americanbankingnews.com)
- TG Therapeutics (TGTX) PT Raised to $27.00 (americanbankingnews.com)
- TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2017 Financial Results and Business Update (finance.yahoo.com)
- TG Therapeutics, Inc. to Host Conference Call on Fourth Quarter and Year-End 2017 Financial Results and Business Update (finance.yahoo.com)
A number of equities analysts have issued reports on TGTX shares. HC Wainwright reiterated a “buy” rating and set a $33.00 target price (up previously from $18.00) on shares of TG Therapeutics in a report on Tuesday, November 14th. B. Riley started coverage on TG Therapeutics in a report on Friday, December 1st. They set a “buy” rating and a $21.50 target price for the company. BidaskClub cut TG Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, January 23rd. Raymond James Financial reiterated a “buy” rating on shares of TG Therapeutics in a report on Tuesday, December 12th. Finally, Zacks Investment Research cut TG Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 13th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $24.60.
TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Thursday, March 8th. The biopharmaceutical company reported ($0.46) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.46). TG Therapeutics had a negative net margin of 77,945.40% and a negative return on equity of 137.47%. The company had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. equities research analysts forecast that TG Therapeutics will post -1.69 EPS for the current year.
In other news, CFO Sean A. Power sold 32,006 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $8.50, for a total transaction of $272,051.00. Following the completion of the transaction, the chief financial officer now directly owns 517,464 shares in the company, valued at approximately $4,398,444. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 16.70% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://sportsperspectives.com/2018/03/13/tg-therapeutics-tgtx-earns-news-impact-score-of-0-18.html.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.